Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism

Hyperparathyroidism Clinical Trial

Official title:

Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00573573
• Other study ID #: GAAD-HT-CTP1
• Status: Active, not recruiting
• Phase: Phase 1
• First received: December 12, 2007
• Last updated: March 23, 2009
• Start date: January 2007
• Est. completion date: July 2009

Study information

• Verified date: March 2009
• Source: GAAD Medical Research Institute Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.

Description:

Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.

We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 2
• Est. completion date: July 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Persons with parathyroid disease

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hyperparathyroidism

Intervention

Radiation:
• Far Infrared Radiation
Far Infrared Radiation (5µm to 20µm wavelength) for 30 to 40 minutes each session.

Locations

Country	Name	City	State
Canada	The Centre for Incurable Diseases	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
GAAD Medical Research Institute Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism.		2 years	No
Secondary	Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes		2 years	No